Risk stratification of chronic heart failure patients by multiple biomarkers - Implications of BNP, H-FABP, and PTX3

Circulation Journal

Volumn 72, Issue 11, 2008, Pages 1800-1805

  Ishino, Mitsunori ^a   Takeishi, Yasuchika ^b   Niizeki, Takeshi ^a   Watanabe, Tetsu ^a   Nitobe, Joji ^a   Miyamoto, Takuya ^a   Miyashita, Takehiko ^a   Kitahara, Tatsuro ^a   Suzuki, Satoshi ^a   Sasaki, Toshiki ^a   Bilim, Olga ^a   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarkers; Chronic heart failure; Risk stratification

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN; PENTRAXIN 3;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HOSPITAL READMISSION; HUMAN; INFLAMMATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; FATTY ACID-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SERUM AMYLOID P-COMPONENT;

EID: 55449130738     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0157     Document Type: Article

References (22)

1. Funk M, Krumholz HM. Epidemiologic and economic impact of advanced heart failure. J Cardiovasc Nurs 1996; 10: 1-10.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
4. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
5. Arimoto T, Takeishi Y, Shiga R, Fukui A, Tachibana H, Nozaki N, et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 2005; 11: 56-60.
6. Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 2007; 13: 120-127.
7. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81.
8. Niizeki T, Takeishi Y, Arimoto T, Takahashi T, Okuyama H, Takabatake N, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J 2005; 69: 922-927.
9. Niizeki T, Takeishi Y, Arimoto T, Nozaki N, Hirono O, Watanabe T, et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 2008; 72: 109-114.
10. Niizeki T, Takeishi Y, Takabatake N, Shibata Y, Konta T, Kato T, et al. Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: Effects of age, gender, and physiologic characteristics. Circ J 2007; 71: 1452-1457.
11. Kitahara T, Takeishi Y, Arimoto T, Niizeki T, Koyama Y, Sasaki T, et al. Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ J 2007; 71: 929-935.
12. Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, et al. Serum resistin is associated with high risk in patients with congestive heart failure: A novel link between metabolic signals and heart failure. Circ J 2007; 71: 460-464.
13. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007; 11: 156-163.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
15. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
16. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: Cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000; 72: 175-186.
17. Glatz JF, Paulussen RJ, Veerkamp JH. Fatty acid binding proteins from heart. Chem Phys Lipids 1985; 38: 115-129.
18. Schaap FG, van der Vusse GJ, Glatz JF. Fatty acid-binding proteins in the heart. Mol Cell Biochem 1998; 180: 43-51.
19. Panteghini M. Standardization activities of markers of cardiac damage: The need of a comprehensive approach. Eur Heart J 1998; 19(Suppl): N8-N11.
20. Pan JP, Liu TY, Chiang SC, Lin YK, Chou CY, Chan WL, et al. The value of plasma levels of tumor necrosis factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure. J Chin Med Assoc 2004; 67: 222-228.
21. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-3067.
22. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, et al. Characterization of the promoter for the human long pentraxin PTX3: Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 1997; 272: 8172-8178.